bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
235 hedge funds and large institutions have $5.86B invested in bluebird bio in 2015 Q2 according to their latest regulatory filings, with 53 funds opening new positions, 71 increasing their positions, 88 reducing their positions, and 24 closing their positions.
121% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 24
100% more funds holding in top 10
Funds holding in top 10: 4 → 8 (+4)
54% more capital invested
Capital invested by funds: $3.8B → $5.86B (+$2.06B)
12% more funds holding
Funds holding: 210 → 235 (+25)
4% more call options, than puts
Call options by funds: $117M | Put options by funds: $112M
19% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 88
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$380M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$108M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$102M |
| 4 |
O
OrbiMed
New York
|
+$64.1M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$61.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$94M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$64.6M |
| 3 |
DM
Deerfield Management
New York
|
-$47.9M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$45.1M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$35.9M |
BLUE Hedge Fund Activity: Q2 2015 in Review
235 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q2 2015, worth a combined $5.86B — up 54% from $3.8B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new BLUE positions and 24 closed out — a net gain of 29 holders — while 71 added to existing stakes and 88 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $380M. The largest seller was Millennium Management, cutting an estimated $94M.
- 235 institutional investors held bluebird bio (BLUE) as of Q2 2015, up from 210 in Q1 2015.
- Funds reported $5.86B of bluebird bio stock for Q2 2015, up 54% quarter-over-quarter.
- 53 funds opened new bluebird bio positions in Q2 2015 and 24 closed out, a net change of +29 holders.
- The largest bluebird bio buyer in Q2 2015 was Baillie Gifford & Co, an estimated $380M added.
- The largest bluebird bio seller in Q2 2015 was Millennium Management, an estimated $94M sold.
Based on aggregated 13F filings for Q2 2015.